Abstract:The ongoing antibiotic-resistance crisis is becoming a global problem affecting public health. Urgent efforts are required to design novel therapeutics against pathogenic bacterial species. Brucella melitensis is an etiological agent of brucellosis, which mostly affects sheep and goats but several cases have also been reported in cattle, water buffalo, yaks and dogs. Infected animals also represent the major source of infection for humans. Development of safer and effective vaccines for brucellosis remains a priority to support disease control and eradication in animals and to prevent infection to humans. In this research study, we designed an in-silico multi-epitopes vaccine for B. melitensis using computational approaches. The pathogen core proteome was screened for good vaccine candidates using subtractive proteomics, reverse vaccinology and immunoinformatic tools. In total, 10 proteins: catalase; siderophore ABC transporter substrate-binding protein; pyridoxamine 5'-phosphate oxidase; superoxide dismutase; peptidylprolyl isomerase; superoxide dismutase family protein; septation protein A; hypothetical protein; binding-protein-dependent transport systems inner membrane component; and 4-hydroxy-2-oxoheptanedioate aldolase were selected for epitopes prediction. To induce cellular and antibody base immune responses, the vaccine must comprise both B and T-cells epitopes. The epitopes were next screened for antigenicity, allergic nature and water solubility and the probable antigenic, non-allergic, water-soluble and non-toxic nine epitopes were shortlisted for multi-epitopes vaccine construction. The designed vaccine construct comprises 274 amino acid long sequences having a molecular weight of 28.14 kDa and instability index of 27.62. The vaccine construct was further assessed for binding efficacy with immune cell receptors. Docking results revealed that the designed vaccine had good binding potency with selected immune cell receptors. Furthermore, vaccine-MHC-I, vaccine-MHC-II and vaccine-TLR-4 complexes were opted based on a least-binding energy score of -5.48 kcal/mol, 0.64 kcal/mol and -2.69 kcal/mol. Those selected were then energy refined and subjected to simulation studies to understand dynamic movements of the docked complexes. The docking results were further validated through MMPBSA and MMGBSA analyses. The MMPBSA calculated -235.18 kcal/mol, -206.79 kcal/mol, and -215.73 kcal/mol net binding free energy, while MMGBSA estimated -259.48 kcal/mol, -206.79 kcal/mol and -215.73 kcal/mol for TLR-4, MHC-I and MHC-II complexes, respectively. These findings were validated by water-swap and entropy calculations. Overall, the designed vaccine construct can evoke proper immune responses and the construct could be helpful for experimental researchers in formulation of a protective vaccine against the targeted pathogen for both animal and human use.

Application of Immunoproteomics in Research on Outer Membrane Protein of Brucella

Identification of potential antigenic peptides of Brucella through proteome and peptidome

Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development

[Prevalence of depression in multiple sclerosis: a review and meta-analysis].

Identification of a protective protein from stationary-phase exoproteome of Brucella abortus

Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine

[Research on the total nucleoprotein and the deoxyribonucleic acids in fibroblasts cultivated in vitro and in Ehrlich tumor cells. A quantitative cytochemical study by microinterferometry and cytophotometry].

New Ways of Thinking About Senescent Bioprosthetic Heart Valve Therapy.

A Novel Recombinant Multi-Epitope Protein Against Brucella Melitensis Infection.

Design of a multi-epitope vaccine candidate against Brucella melitensis

Human papillomavirus vaccines for the prevention and treatment of cervical cancer.

[Personality characteristics in patients with Wilson's lichen ruber planus].

Proteomic and Antibody Profiles Reveal Antigenic Composition and Signatures of Bacterial Ghost Vaccine of Brucella abortus A19

Proteomics Exploration of Brucella melitensis to Design an Innovative Multi-Epitope mRNA Vaccine

Novel scoring methods in virtual ligand screening.

Wiggler-field effects on the space-charge waves of a Raman free-electron laser.

Loss of trifluralin from clay and loam soils containing aged and freshly applied residues

Development of a novel multi-epitope vaccine for brucellosis prevention

Proteome-Wide Screening of Potential Vaccine Targets against Brucella melitensis

Two cervical preparation regimens prior to surgical abortion at 10–14 weeks of gestation: A randomized clinical trial

The Brucella Melitensis M5-90ΔmanB Live Vaccine Candidate is Safer Than M5-90 and Confers Protection Against Wild-Type Challenge in BALB/c Mice.